Fort, L.P. Blueprint Medicines Corp Transaction History

Fort, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$54.1 - $110.08 $114,854 - $233,699	-2,123 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$94.25 - $115.99 $146,370 - $180,132	-1,553 Reduced 42.25%	2,123 $227,000
Q3 2021 Nov 12, 2021	SELL	$80.98 - $109.47 $101,063 - $136,618	-1,248 Reduced 25.35%	3,676 $378,000
Q2 2021 Aug 13, 2021	SELL	$82.78 - $101.0 $96,521 - $117,766	-1,166 Reduced 19.15%	4,924 $433,000
Q1 2021 May 14, 2021	BUY	$90.71 - $108.28 $294,263 - $351,260	3,244 Added 113.98%	6,090 $592,000
Q4 2020 Feb 12, 2021	BUY	$92.08 - $124.48 $262,059 - $354,270	2,846 New	2,846 $319,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Fort, L.P., based on Form 13F filings with the SEC.

Stay updated on Fort, L.P. with notifications on news.